9 Sources of evidence considered by the Committee

9 Sources of evidence considered by the Committee

A. The Evidence Review Group (ERG) report for this appraisal was prepared by Kleijnen Systematic Reviews:

  • Riemsma R, Joore M, Tomini F et al., Enzalutamide for the treatment of metastatic hormone relapsed prostate cancer previously treated with a docetaxel-containing regimen, August 2013

B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the 2 appraisal consultation documents. Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to give their expert views. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I. Manufacturer/sponsor:

  • Astellas Pharma

II. Professional/specialist and patient/carer groups:

  • Prostate Cancer UK

  • Royal College of Nursing

  • Royal College of Physicians

  • Right Angle

III. Other consultees:

  • Department of Health

  • Welsh Government

IV. Commentator organisations (did not provide written evidence and without the right of appeal):

  • Commissioning Support Appraisals Service

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Healthcare Improvement Scotland

  • Medicines and Healthcare products Regulatory Agency

C. The following individuals were selected from clinical specialist and patient expert nominations from the consultees and commentators. They gave their expert personal view on enzalutamide by attending the Committee meetings and providing written evidence to the Committee. They were also invited to comment on both appraisal consultation documents.

  • Dr Amit Bahl, Consultant Clinical Oncologist, Bristol Haematology and Oncology Centre, nominated by NCRI/RCP/RCR/ACP/JCCO – clinical specialist

  • Dr Simon Russell, Consultant Medical Oncologist, Guys and St Thomas' Hospital, nominated by Astellas – clinical specialist

  • Hugh Gunn, nominated by Prostate Cancer Support Federation – patient expert

  • Stuart Watson, nominated by Prostate Cancer UK – patient expert

D. Representatives from the following manufacturer/sponsor attended the Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Astellas Pharma

  • National Institute for Health and Care Excellence (NICE)